Jump to content

Abacavir/lamivudine/zidovudine

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Rivasiker (talk | contribs) at 19:13, 14 June 2018 (Abacavir is a nucleoside (and not nucleotide) reverse transcriptase inhibitor because it does not contain any phosphorylated residue). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Abacavir/lamivudine/zidovudine
Combination of
AbacavirNucleoside analogue reverse transcriptase inhibitor
LamivudineNucleoside analogue reverse transcriptase inhibitor
ZidovudineNucleoside analogue reverse transcriptase inhibitor
Clinical data
Trade namesTrizivir
AHFS/Drugs.comFDA Professional Drug Information
MedlinePlusa687007
Routes of
administration		Oral
ATC code
Legal status
Legal status
Identifiers
CAS Number
ChemSpider
KEGG
NIAID ChemDB
 ☒NcheckY (what is this?)  (verify)

Abacavir/lamivudine/zidovudine, sold under the trade name Trizivir, is a medication for HIV infection.[1] It is a fixed dose combination of three reverse transcriptase inhibitors patented by GlaxoSmithKline and marketed by a joint venture with Pfizer, ViiV Healthcare:[2]

It is indicated in the treatment of AIDS/HIV.[3] For this purpose, the combination is very useful in pregnant women to decrease the risk of mother-to-child transmission.[4]

The combination of drugs helps to reduce HIV's resistance (through mutation) to the drugs individually. Of the three, AZT and ABC have passed out of United States patent protection.

In December 2013, Lupin Limited launched a generic version of Trizivir.[5][6] As of 2016 the wholesale cost for a typical month of medication in the United States is more than 669.30 USD.[7]

See also

References

  1. ^ Opravil, Milos; Hirschel, Bernard; Lazzarin, Adriano; Furrer, Hansjakob; Chave, Jean‐Philippe; Yerly, Sabine; Bisset, Leslie R.; Fischer, Marek; Vernazza, Pietro; Bernasconi, Enos; Battegay, Manuel; Ledergerber, Bruno; Günthard, Huldrych; Howe, Colin; Weber, Rainer; Perrin, Luc (May 2002). "A Randomized Trial of Simplified Maintenance Therapy with Abacavir, Lamivudine, and Zidovudine in Human Immunodeficiency Virus Infection". The Journal of Infectious Diseases. 185 (9): 1251–1260. doi:10.1086/340312. PMID 12001042.
  2. ^ InPharm.com: GlaxoSmithKline-Pfizer launch HIV joint venture Archived January 4, 2012, at the Wayback Machine
  3. ^ Drugs.com: Trizivir
  4. ^ Horvath, Tara; Madi, Banyana C; Iuppa, Irene M; Kennedy, Gail E; Rutherford, George W; Read, Jennifer S.; Horvath, Tara (2009). "Interventions for preventing late postnatal mother-to-child transmission of HIV". Cochrane Database Syst Rev (1): CD006734. doi:10.1002/14651858.CD006734.pub2. PMID 19160297.
  5. ^ Monthly Prescribing Reference (MPR)
  6. ^ Lupin Pharma
  7. ^ "NADAC as of 2016-12-07 | Data.Medicaid.gov". Centers for Medicare and Medicaid Services. Retrieved 12 December 2016.
Stub icon

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Abacavir/lamivudine/zidovudine&oldid=845879250"